New York State Teachers Retirement System Has $5.44 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

New York State Teachers Retirement System decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 87,709 shares of the medical equipment provider’s stock after selling 1,003 shares during the quarter. New York State Teachers Retirement System owned about 0.13% of Lantheus worth $5,438,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC acquired a new position in shares of Lantheus during the 4th quarter worth approximately $1,385,000. Natixis Advisors L.P. increased its holdings in shares of Lantheus by 172.8% during the 3rd quarter. Natixis Advisors L.P. now owns 52,530 shares of the medical equipment provider’s stock worth $3,649,000 after acquiring an additional 33,273 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Lantheus by 41.9% during the 3rd quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock worth $90,387,000 after acquiring an additional 384,093 shares during the last quarter. Boston Partners increased its holdings in shares of Lantheus by 15.2% during the 3rd quarter. Boston Partners now owns 512,930 shares of the medical equipment provider’s stock worth $35,326,000 after acquiring an additional 67,729 shares during the last quarter. Finally, Lazard Asset Management LLC increased its holdings in shares of Lantheus by 60.5% during the 3rd quarter. Lazard Asset Management LLC now owns 336,946 shares of the medical equipment provider’s stock worth $23,410,000 after acquiring an additional 126,947 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold a total of 94,545 shares of company stock worth $6,168,153 in the last ninety days. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

NASDAQ:LNTH opened at $60.79 on Friday. The stock has a fifty day moving average price of $60.13 and a 200-day moving average price of $63.15. The company has a market cap of $4.17 billion, a price-to-earnings ratio of 13.10 and a beta of 0.53. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $100.85.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The firm had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LNTH. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. William Blair downgraded Lantheus from an “outperform” rating to a “market perform” rating in a research note on Monday, December 18th. TheStreet downgraded Lantheus from a “b-” rating to a “c” rating in a research note on Monday, December 18th. B. Riley reduced their price target on Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a research note on Wednesday, January 10th. Finally, Truist Financial restated a “buy” rating and issued a $82.00 price target (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.14.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.